p16 mutation frequency and clinical correlation in head and neck cancer

Acta Otolaryngol. 1999 Mar;119(2):285-8. doi: 10.1080/00016489950181837.

Abstract

The tumor suppressor gene p16, when altered, has been shown to play a role in oncogenesis in many different tumor types including head and neck cancer. The goal of this study was to analyse alterations to p16 in squamous cell carcinoma (SCC) of the head and neck and to correlate these with clinical outcome. RNA was isolated from 26 SCC head and neck tumors and from 24 matched controls. A reverse transcription polymerase chain reaction was utilized to generate p16 cDNA, which was sequenced and analysed for alterations. In the 26 patient group 58% of the tumors had a p16 alteration, which were characterized by: 8 deletions, 1 insertion/deletion, 4 point mutations and 2 with no p16 expression. In 24 matched normal tissue samples there were no p16 alterations. Those patients with p16 alterations appear to have survival rates comparable to those without p16 alterations, although patients with p16 alterations appear to have more recurrences.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Carcinoma, Squamous Cell / genetics*
  • Carcinoma, Squamous Cell / mortality
  • Case-Control Studies
  • DNA, Neoplasm / genetics
  • Genes, p16 / genetics*
  • Head and Neck Neoplasms / genetics*
  • Head and Neck Neoplasms / mortality
  • Humans
  • Mutation*
  • Neoplasm Recurrence, Local / genetics
  • RNA, Neoplasm / genetics
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • DNA, Neoplasm
  • RNA, Neoplasm